Tarvainen T, et al. - Researchers investigated the noninferiority of hydrocortisone vs pasireotide in reducing pancreatic surgery complications. From May 19, 2016, to December 17, 2018, they performed a randomized clinical trial including 126 patients undergoing partial pancreatectomy. Patients were assigned to receive either pasireotide, 900 μg, subcutaneously twice a day for 7 days or hydrocortisone, 100 mg, intravenously 3 times a day for 3 days. Patients receiving pasireotide exhibited lower mean Comprehensive Complication Index score (a measurement of overall postoperative morbidity) by –6.16 points; the lower limit of the 90% CI crossed the prespecified noninferiority margin (–9). In subgroup analyses of patients undergoing distal pancreatectomy, the pasireotide vs hydrocortisone group had a significantly lower mean Comprehensive Complication Index score (10.3 points). Findings thereby do not support the noninferiority of hydrocortisone vs pasireotide; pasireotide was suggested to be possibly more effective in reducing postoperative complications in patients undergoing distal pancreatectomy.